Catalent Introduces New Next-Generation Cell-Line Development Technology
The technology is set to heighten the company’s GPEx expression platform through the utilization of a glutamine synthase knock-out Chinese hamster ovary cell line.
Catalent announced it launched its new next-generation cell line development technology, GPEx Boost, on Nov. 4, 2019. The technology is set to heighten the company’s GPEx expression platform through the utilization of a glutamine synthase knock-out Chinese hamster ovary cell line.
While maintaining the standard GPEx platform, the GPEx Boost can improve titers up to four-fold, possibly to 10 g/L for standard monoclonal antibodies, according to the company. The new technology has also shown improvement in cell growth and viability, resulting in shortened developmental timelines for projects by combining it with the Berkeley Lights’ Beacon optofluidic platform, and ambr automated micro bioreactors.
“GPEx Boost technology builds on the proven GPEx platform to enable significantly higher productivity and stability for even the most difficult-to-express proteins,” said Michael Riley, president, United States region of Catalent Biologics, in a press release. “This new proprietary platform can also be combined with other state-of-the-art technology, such as the Beacon system, to provide a unique development tool for our customers.”
Source: Catalent
Diving Deep into Carrier-Based Formulation and Process Optimization
December 23rd 2024Carrier-based formulations for dry powder inhalers are carefully designed to transport extremely small particles into the lungs. Jet milling can be used to micronize these particles, with both high and low shear mixing processes used to formulate mixtures capable of carrying the fine API particles into the deep lung. This paper looks at the requirements for pulmonary delivery via carrier-based inhaled powder formulations, and how jet milling can be used to manufacture effective and stable materials for these formulations
Molecular Properties of PROTACs and the Relationship to Formulation Design
December 20th 2024Analyzation of a diverse set of PROTAC (Proteolysis Targeting Chimeras – a class of TPDs) structures and their calculated properties, identifying key structure-property trends that contribute to low oral bioavailability.
